Allergy Therapeutics plc has announced the exercise of options and the issuance of new ordinary shares. A total of 5,229,074 new ordinary shares of £0.001 each have been issued following the exercise of options by certain current and former employees. Of these, 5,197,965 options were exercised as a result of recent equity financing that constituted a change of control for the purposes of the Company's Long Term Share Incentive Plan, and 31,109 options were exercised in connection with proposals made to the holders of those options pursuant to Rule 15 of the Code. The new ordinary shares have been admitted to trading on AIM and rank pari passu with the existing shares of the Company.
As a result of the exercise of options, Allergy Therapeutics now has 4,758,946,227 ordinary shares of £0.001 each in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Allergy Therapeutics is a pharmaceutical company focused on the development and commercialization of allergy immunotherapy products.